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Abstract
Background: As well as being a risk factor for cardiovascular disease, hypertension is also a health condition in its own right.
Risk prediction models may be of value in identifying those individuals at risk of developing hypertension who are likely to
benefit most from interventions.
Methods and Findings: To synthesize existing evidence on the performance of these models, we searched MEDLINE and
EMBASE; examined bibliographies of retrieved articles; contacted experts in the field; and searched our own files. Dual
review of identified studies was conducted. Included studies had to report on the development, validation, or impact
analysis of a hypertension risk prediction model. For each publication, information was extracted on study design and
characteristics, predictors, model discrimination, calibration and reclassification ability, validation and impact analysis.
Eleven studies reporting on 15 different hypertension prediction risk models were identified. Age, sex, body mass index,
diabetes status, and blood pressure variables were the most common predictor variables included in models. Most risk
models had acceptable-to-good discriminatory ability (C-statistic.0.70) in the derivation sample. Calibration was less
commonly assessed, but overall acceptable. Two hypertension risk models, the Framingham and Hopkins, have been
externally validated, displaying acceptable-to-good discrimination, and C-statistic ranging from 0.71 to 0.81. Lack of
individual-level data precluded analyses of the risk models in subgroups.
Conclusions: The discrimination ability of existing hypertension risk prediction tools is acceptable, but the impact of using
these tools on prescriptions and outcomes of hypertension prevention is unclear.
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Introduction
Hypertension has major public health and economic implica-
tions [1,2]. Worldwide, raised blood pressure is estimated to cause
around 13% deaths [3]. A growing proportion of people have
prehypertension, that is, blood pressure which is higher than
normal but does not meet the threshold for hypertension; in the
US, for example, up to 31% of the population are so classified
[4,5]. The lifetime risk of developing hypertension may be as high
as 90% [6] and over a third of adults with prehypertension
progress to hypertension within a 4 year period [7].
Randomized trials of treating individuals with prehypertension
suggest that hypertension onset can be prevented or delayed with
drug treatment [8], or lifestyle modification [9,10], or both. However,
the most appropriate strategies to achieve effective hypertension
prevention in practice are unclear. One strategy is to target
individuals who are at high risk of developing hypertension. Evidence
from prospective cohort studies suggests that the risk for progression
to hypertension is not only determined by the status of prehyperten-
sion but depends on several factors, such as age, body mass index,
blood pressure, smoking, family history, and physical inactivity [7].
Combining these known risk factors into a multivariable model for
risk stratificationmay allow large-scale identification of the segment of
the population that would benefit the most from primary prevention
of hypertension. While multivariable models to predict hypertension
are increasingly common, the total evidence on their performance
has not been synthesized. Thus, unsurprisingly, predictive models are
seldom being utilized in clinical practice in order to improve decision
making and outcomes of hypertension prevention.
We report on the first systematic review of studies describing
risk equations to predict hypertension. Our objective is to identify
existing risk engines and, to summarize evidence as to their
performance. Additionally, we will provide an overview of
evidence of the impact of these hypertension risk models on
decision making and the outcomes of care. Ultimately, our aim is
to provide healthcare providers with a balanced account of the
performance of the existing hypertension risk models.
Methods
We conducted literature searches to identify all risk models
developed to predict the future occurrence of hypertension among
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people with normal blood pressure or classified as prehypertension
[11]. We also searched for all studies that applied existing
hypertension prediction models either in the population from
which the model was developed or in different populations. Lastly,
we searched for reports describing impact analysis of the
hypertension risk models – that is, studies examining the influence,
if any, of adopting a risk model on decision making and the
outcomes of care.
Identification of Studies on Model Development and
Validation
Data sources and searches. We utilized a four-pronged
approach to identifying relevant publications. First, we searched
electronic databases PubMed (Medline) and EMBASE from their
inception to April 2013, for English or French language studies of
development and/or validation of hypertension risk prediction
models. We used a combination of search terms related to
hypertension and prediction. The search strategies are provided in
detail in Text S1, and the last search date was April 30, 2013.
Second, we manually searched the reference sections of retrieved
publications, and identified any citations through the ISI Web of
Science for additional published and unpublished data. Third, we
contacted experts in the field, and finally, we searched our own
files.
Study selection. Two experienced evaluators (JBE, APK)
independently identified articles and sequentially screened them
for inclusion (Figure 1). Where necessary, the full text of articles
and/or supplemental materials (tables and appendices) was
reviewed before deciding on the inclusion. Disagreements were
solved by a third investigator (GDB).
Eligible articles had to report on a risk assessment tool (equation
and/or score) for predicting hypertension occurrence, and be
based on adult human populations. Reporting of quantitative
measures of the performance of models was preferable but not
necessary for inclusion. We excluded studies that only reported
measures of association between risk factors and incident
hypertension, and simulation studies. We also excluded studies
of prediction of gestation-related hypertensive disorders (e.g.,
preeclampsia).
Data extraction and quality assessment. Two experi-
enced reviewers (JBE and APK) independently conducted the data
extraction and quality assessment. We did not use a particular
framework for quality assessment, as there is no consensus over a
quality assessment framework for risk prediction models [12].
From each study, we extracted data on study design, setting,
population characteristics, number of patients in the derivation
and validation cohorts, the number of participants with the
outcome of interest, the number of candidate variables tested as
predictor and the numbers and list of those included in the final
model, as well as the type of statistical model used. For the
discriminative ability of models, we extracted information on the
area under the receiver operating characteristic curve (AUC) or C-
statistic. To describe model calibration, we extracted data on the
difference between the observed and predicted rates of hyperten-
sion, as well as the p-value of the corresponding test statistic. For
the assessment of reclassification, we extracted the net reclassifi-
cation improvement (NRI) and integrated discrimination im-
provement index (IDI) values, as well as their respective 95% CIs
and p-values, when available [13,14].
Data synthesis and analysis. The wide range of metrics
used for the assessment of the predictive ability of hypertension
risk models, and the heterogeneity in both the risk factors used for
prediction and their number, as well as the study designs
precluded any reliable data synthesis in the form of meta-analysis.
We therefore opted to conduct a narrative synthesis of the
evidence. However, as a number of studies evaluated the
Framingham hypertension risk model [15], thus representing a
subgroup of less heterogeneous studies, we applied the random-
effects model meta-analyses to combine the estimates of the AUC
from those studies and assessed the between-study heterogeneity,
with the use of the R statistical software version 2.13.0 [13-04-
2011], (The R Foundation for Statistical Computing, Vienna,
Austria).
Impact Analysis of Hypertension Risk Models
Impact analysis studies were captured by: 1) scanning the
publications identified through the search strategy for model
development and validation, and 2) applying the search strategy
for impact studies proposed by Reilly and Evans [16], which
combines the model’s acronym or name of the cohort or first
author, with specific search term combination (Text S2).
Results
The study selection process is described in Figure 1. After
scanning titles of the citations identified through searches, 467
abstracts were selected for in-depth evaluation and 33 full-text
publications were reviewed. After all exclusions, eleven articles
reporting on 15 different hypertension risk prediction models met
the eligibility criteria and were included in the review.
Table 1 summarizes the characteristics of studies from 11
publications that report on the development of hypertension risk
prediction models. All the models were developed using cohort
studies with incident hypertension as the outcome of interest.
Populations, Outcomes and Risk Factors
Ten of the 13 hypertension risk algorithms were developed from
samples drawn from populations in the USA (n= 6) [15,17,18,19],
UK (n= 4) [20,21], or Sweden (n= 1) [22]; study participants
mostly seemed to comprise Whites. One study included only
Iranian [23], one only Chinese participants [24], and another only
Koreans [25]. The number of people included in the studies
ranged from 1,103 to 11,407 and the age of participants at
baseline ranged from less than 25 to 69 years or more. The study
population for three models comprised only women [18], and for
one model only men [17]. The length of follow-up in the studies
ranged from 4 to 30 years.
Except for one study [17], outcomes were defined using the
Joint National Committee (JNC) - VII definition of hypertension
(i.e., systolic/diastolic blood pressure .=140/90 mmHg or use of
blood pressure lowering medications) [11]. Three studies clearly
provided data on the numbers of candidate variables tested for
inclusion in the models [15,18,19]. This number ranged from 11
to 23 [15,18], giving estimates of the number of incident
hypertension cases per candidate variable ranging from 72 to
345 [15,18]. The predictors most commonly included in the final
prediction models were: age, sex, body mass index, systolic blood
pressure, and diastolic blood pressure, parental history of
hypertension, and cigarette smoking (Table S1). Additionally, a
variable for the interaction term between age and blood pressure
variable was included in four models [19,21]. Biomarkers, such as
C-reactive protein (CRP) [18], apolipoprotein A [18], and uric
acid [24] were included in one model.
One model was derived using Cox regression [17], five models
using logistic regressions [18,19,22] and the rest were developed
using Weibull regression models [20,21,23,24,25]. All studies
reported the original model with beta coefficients and 4 studies
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presented additional point-based scoring systems or charts
[15,23,24,25].
Performance of Risk Prediction Models
Table 1 shows the performance of the various hypertension risk
models. All the included studies reported a C-statistic ranging from
0.70 [18] to 0.80 [20], indicating an acceptable-to-good discrim-
inatory capability. Ten scores were internally validated through
split-sample validation (nine models) or bootstrapping (one model).
Ten risk models had an estimate of calibration, the Hosmer-
Lemeshow test statistic and accompanying p-values, which
generally indicated good calibration [15,18,20,21,23,24,25].
Figure 1. Identification of relevant publications.
doi:10.1371/journal.pone.0067370.g001
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Validation of Hypertension Risk Prediction Models
Table 2 shows the results of the external validation of
hypertension risk models. Two of the risk models (Framingham
and Johns Hopkins) were externally validated. The Framingham
hypertension risk model was validated in four independent
populations [20,24,25,26], while the Hopkins model was validated
in one [24]. The C-statistic in validation studies (0.71 to 0.81) was
generally lower than that in the derivation sample, but always
acceptable. The change from the original C-statistic when the
model was first derived ranged from 20.08 to +0.01 (Table 2),
being negative or null except in one case where it was positive
[20], thus indicating a generally lower discrimination in validation
populations.
In a random-effects meta-analysis (Figure S1), pooled AUC for
prediction of hypertension risk using the Framingham risk
equation was 0.78 [95% confidence interval (CI): 0.75 to 0.81]
in the four cohorts that explored the performance of this risk
equation although significant heterogeneity (I2 = 92.5%) was
evident (p,0.001).
Model Improvements and Head-to-head Comparisons
Three studies examined the impact on the predictive capacity of
the hypertension model by adding additional variables [21,22,24].
The Whitehall II study assessed whether prediction with the
Framingham risk model was significantly improved after reclas-
sification on the basis of new scores [21], including repeat
measurement of variables in the model (NRI 9.3% (95% CI: 4.2 to
14.4), utilizing an average of blood pressure measurements (NRI:
5.8% [95% CI: 0.1 to 11.4]), and the value of usual plus current
blood pressure values (NRI: 5.8% [95% CI: 0.1 to 11.4]). The
findings indicated modest or no significant improvement in
predictive performance. The Hopkins score investigators reported
a significant improvement after adding biochemical factors
(glucose level, white blood cell count, uric acid) to traditional
hypertension risk factors; the difference in AUC was 0.005
(p = 0.17), NRI was 7.0% (95% CI: 3.7 to 10.3, p = 0.0002) and
IDI was 1.0 (95% CI: 0.7 to 1.3, p,0.0001) [24]. The
performance of a non-genetic Swedish hypertension risk model
was not improved by the addition of a genetic risk score variable
based on 29 independent single nucleotide polymorphisms. The
AUC for the non-genetic variables-based model was 0.662 (95%
CI: 0.651–0.672) and increased to 0.664 (95% CI: 0.653–0.675)
with inclusion of genetic variables [22].
Impact Analysis of Hypertension Prediction Models
We found no studies that have assessed the impact of adopting
hypertension risk scores on the processes of care and outcomes of
care for people without hypertension.
Discussion
This systematic review shows the feasibility of assessing
individual’s risk of acquiring a diagnosis of hypertension among
people with high or normal blood pressure using a combination of
commonly assessed variables. By representing a primordial
approach, these multifactorial risk models for predicting hyper-
tension occurrence add to traditional cardiovascular prediction
that have been focused on disease endpoints rather than risk
factors. However, most existing hypertension risk models are still
at the early stages of the development and evaluation process, and
only two of them have been tested in populations different from
those used to develop the models.
Strengths of Existing Models and their Utility for Patient
Care
The variables used in prediction models were largely the same
across various age groups, and are generally assessable in routine
practice. The discriminative ability of existing models was
generally acceptable-to-good in both the derivation and validation
samples. With one exception [26], the included studies demon-
strated that extra predictive information is gained when other
variables are factored into a risk model in addition to an
individual’s current blood pressure levels for predicting the
probability of acquiring a diagnosis of hypertension. Furthermore,
hypertension per se antedates many cardiovascular diseases such
as heart failure [27] and stroke, and is associated with a shorter life
expectancy [28]. Thus, prevention of new-onset hypertension may
prevent the emergence of a risk factor for hard outcomes,
representing primordial rather than primary or secondary
prevention. Models for predicting hypertension occurrence
therefore have potential public health and clinical applications in
the prevention hypertension.
Opportunities for Improving the Uptake of Hypertension
Prediction Models in Practice
Practice guidelines currently recommend the use of multivar-
iable risk models as the appropriate basis for cardiovascular
diseases (CVD) risk stratification and prescription of risk reducing
therapies in routine care [29,30]. The most recommended
prediction algorithms for this purpose are CVD models which
incorporate data on routinely measured conventional risk factors
[31,32] which are also common to existing hypertension
prediction models. There is therefore an opportunity at no extra
cost for harnessing CVD and hypertension risk predictions in
routine care.
Using hypertension prediction models in routine care has
several potential advantages, including tailoring the prescription
and intensity of preventive solutions in those at high risk of
progression to hypertension, and improving shared decision
making through accurate risk communication to people at high
risk, with potential positive impact on adherence to prescribed
interventions. Besides routine clinical settings, hypertension risk
scores can also be used 1) to select people at high risk for inclusion
in clinical trials of hypertension prevention; 2) to project the future
burden of hypertension at a population level, and 3) to allocate
resources based on mean levels of the various components of the
hypertension risk score in the communities. For all these
applications, estimates of hypertension risk from predictions
models must be accurate and valid.
Limitations of Existing Models and Perspectives for
Future Research
None of the existing hypertension models was developed using
data specifically collected for risk modelling purpose; thus raising
concerns about the completeness and measurement precision of
the predictors and outcomes included in the models [33]. Other
potential drawbacks that may have affected model performance
included dichotomisation of continuous variables prior to model-
ling, linearity assumption without formal testing and exclusion of
participants with missing values on predictor/outcome variables.
One model was published without indicators of performance
during the derivation process [17]. For models that provided
measures of performance, these were mostly based on the direct
application of the model on the derivation sample (apparent
performance), or performance measures from internal validation
(split-sample or bootstrap). The apparent performance may be
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overoptimistic, and thus internal validation only provides new
users with a rough idea about what to expect when applying the
model to their own populations. Calibration was less commonly
assessed or reported during the derivation process, although it is
commonly agreed that calibration is largely affected by the
background risk which varies across populations. Consequently
models need updating through recalibration procedures to provide
accurate estimate of the risk in new populations. There have been
attempts to recalibrate the Framingham hypertension risk score in
new populations [20].
External validation of a model in new populations is a key step
before it can be recommended for extensive use. Only two of the
13 hypertension prediction models have been tested on different
populations [15,17], and only a few times [20,24,26]. With regard
to the most tested model, the Framingham hypertension risk
model [15], our meta-analysis suggests that the model would
perform equally well among whites in different settings [20,26] but
not necessarily in other ethnic groups [24]. Hence, more
validation studies of existing models are needed, ideally by
different group of investigators to guarantee their generalizability
to a larger number of people.
In addition to providing mathematical equations, some inves-
tigators provided point-scoring systems [15,23,24]. While the
performance of the point-scoring format of risk estimation may be
lower than that of the original model, such a presentation of risk
might facilitate the use of these tools among health care providers
who may not be familiar with complex mathematical formulas,
and consequently improve the uptake of the risk prediction tools in
various settings [34]. Some context- specific efforts may also be
required to derive the appropriate cut-off for defining high-risk
status when those models are integrated in guidelines for
screening. However, prior confirmation that the implementation
of hypertension risk prediction models will affect the behavior of
healthcare providers and improve outcomes of care is necessary.
At present, no implementation trial of hypertension risk prediction
models has been conducted.
One model relied on self-reported blood pressure/hypertension
status solely to define the incidence of the outcome [18];
replication with measured blood pressure is needed to test the
validity of these findings. Two studies indicated the change in the
method used to measure blood pressure over the course of the
cohort study [20,21]; this was probably also the case in the other
cohorts. Such a change in the measurement method may have
affected the incidence of hypertension, and thus the performance
of the risk score. Some of the risk score excluded people with
diabetes [15,20], thus these may not be applicable to that segment
of the population. In most studies, diagnostic of high BP was based
on a single visit rather than repeated visits, however one study that
incorporated previous blood pressure records or estimates of
average or usual blood pressure in in risk prediction models
indicated that these may not improve the prediction of future
hypertension [21].
Participants to the reviewed studies comprised mostly whites. A
homogenous population does not allow assessment of the full
extent of the variability in hypertension risk. This is a drawback
given that racial/ethnic groups are particularly prone to hyper-
tension (e.g., people of African descent). Future studies should
therefore incorporate more subjects of different ethnic back-
ground.
Few studies examined the incremental predictive value of novel
circulating or genetic markers of future hypertension in existing
models. Matrix remodeling biomarkers (inhibitor of metallopro-
teinase-1 [TIMP-1] and metalloproteinase-9 [MMP-9]) [35],
inflammatory markers (C-reactive protein and plasminogen
activator inhibitor-1) [36], urinary albumin/creatinine ratio [36],
and several genetic markers [37] have been shown to be associated
with hypertension, and may be useful for hypertension risk
stratification. However, some of these factors may not always be
readily assessable or available in all settings, or might require more
complex judgment and interpretation.
Strengths and Limitations of the Review
The strengths of this review include the exclusion of studies that
only reported effect estimates for independent association of risk
factors with hypertension. Hitherto, the performance of existing
hypertension risk models in terms of discrimination, calibration,
and reclassification had not been critically examined. The current
review has summarized those performance measures, and
identified the gaps in the evidence on the prognostic ability of
the existing risk prediction models. This will form the basis for
future improvement. Our study is very informative as to whether
or not to incorporate risk models for predicting hypertension in
guidelines for evaluation and management of elevated blood
pressure. Evidence for such an inclusion would be reinforced by
additional studies of external validation of risk scores, as well as
studies of the impact of their use on outcomes. The main limitation
of this review is the lack of individual-level data that could have
allowed a pooled analysis of the performance of models and
subgroup analyses. Our ability to assess publication bias was also
limited. Direct comparison of risk models was also limited by the
lack of some relevant information in some of the published
development or validation studies. Standardized reporting of the
results of risk models will help avoid mistakes such as inadequate
description of the performance of models, or not presenting the
results in a way that can be used by clinicians. Better reporting of
development and validation studies is needed to help clinicians
and other decision makers identify relevant models with potential
clinical value. Furthermore, the use of standard terms and
nomenclature in studies of risk prediction models will allow the
different laboratory, clinic, and population disciplines to interact,
and for findings to be interpreted appropriately and consistently by
clinicians, patients and public health practitioners.
Conclusions
Current multifactorial risk models for predicting hypertension
occurrence have an acceptable-to-good discriminative ability.
However, before these tools are incorporated in guidelines, their
calibration and external validation as well as incremental predictive
power beyond the prehypertension status alone. Future randomized
controlled trials are needed to determine the impact of adopting risk
models on outcomes of care. Cost-effectiveness analyses of the
application of this primordial prevention strategy would be crucial
in future assessments of hypertension prediction models.
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